Crystal Crop Protection IPO Day 2: Issue Subscribed Over 2 Times as GMP Signals Around 6% Listing Premium
The Crystal Crop Protection IPO is attracting investor attention on its second day of bidding, with the public issue subscribed more than two times as of November 19, 2026. The agrochemical company’s...
The Crystal Crop Protection IPO is attracting investor attention on its second day of bidding, with the public issue subscribed more than two times as of November 19, 2026. The agrochemical company’s initial public offering (IPO) has also recorded interest across retail and institutional investor categories. However, its grey market premium (GMP) has moderated, suggesting that investors should look beyond possible listing gains before making a decision.
Crystal Crop Protection IPO Subscription Status
According to data reported by The Economic Times, the issue was subscribed 2.11 times as of 12:19 PM on November 19. Investors had placed bids for approximately 2.57 crore shares against 1.22 crore shares on offer.
The retail investor category was subscribed 2.22 times, while the qualified institutional buyer (QIB) portion received bids for 2.07 times its reserved shares. The employee category recorded stronger demand, with subscription of around 4.11 times.
The IPO opened on November 18 and will close on November 20, 2026.
Crystal Crop Protection IPO GMP Today
The grey market premium for Crystal Crop Protection stood at around ₹17 per share on November 19, according to market reports. At the upper issue price of ₹272, this indicates an estimated listing price of approximately ₹289, or a potential premium of around 6.25%.
However, the GMP is an unofficial market indicator. It is not regulated by stock exchanges and does not guarantee the actual listing price or investor returns. It can change before the shares begin trading.
The latest figure is also lower than the ₹19 premium reported on November 18, showing why investors should avoid treating grey-market estimates as assured profits.
IPO Price Band, Lot Size and Important Dates
Crystal Crop Protection has fixed its IPO price band at ₹259 to ₹272 per share. The issue size is approximately ₹455.49 crore, comprising a fresh issue of around ₹354.77 crore and an offer for sale (OFS) of approximately ₹100.71 crore.
The minimum application size is 55 shares. At the upper price band, retail investors need at least ₹14,960 to apply for one lot.
The allotment is expected to be finalised on November 23, while the shares are tentatively scheduled to list on the BSE and NSE on November 26, 2026.
What Does Crystal Crop Protection Do?
Crystal Crop Protection operates in India’s agricultural solutions market. Its business includes crop protection products such as herbicides, fungicides and insecticides, along with natural crop solutions and seeds.
The company also focuses on research and development to support its product portfolio. According to Business Standard’s report on the IPO, its seeds business recorded a revenue compound annual growth rate of 28.49% between FY24 and FY26.
This presence across multiple agricultural segments gives the company exposure to different parts of the farming value chain.
Should Investors Look Beyond the GMP?
The IPO has received a positive long-term recommendation from Anand Rathi, although the brokerage has also described the valuation as fully priced. At the upper price band, the company is valued at around 30.6 times its FY26 earnings, according to the brokerage’s assessment.
This valuation makes it important for investors to examine the company’s earnings growth, business performance and ability to maintain profitability. Demand for agricultural products, competition, input costs and regulatory developments are also relevant factors to assess in the agrochemical industry.
The Crystal Crop Protection IPO has attracted encouraging subscription demand, but a strong response does not automatically make an issue attractively valued.
Investors should read the company’s offer documents, understand the risks and assess their own financial goals before applying. The GMP should be treated as a sentiment indicator, not an investment recommendation.
Disclaimer: This article is for information purposes only and does not constitute investment advice. IPO investments involve market risks. Consult a SEBI-registered investment adviser before making investment decisions.



No Comment! Be the first one.